Protagonist Therapeutics announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be presented at the 33rd United European Gastroenterology Week (UEGW) in Berlin. The presentation is scheduled as a brief oral session on October 7, 2025.
This announcement follows earlier positive topline results from the ANTHEM-UC trial, which met its primary endpoint of clinical response across all dose groups. The upcoming presentation will provide a more detailed look at the full dataset.
The presentation at a prominent European gastroenterology conference underscores the importance of icotrokinra's potential in ulcerative colitis. This event is a key catalyst for further understanding the drug's efficacy and safety profile in this indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.